Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma
Claire Dendle, Michael Gilbertson, Tim Spelman, Rhonda L Stuart, Tony M Korman, Karin Thursky, Stephen Opat, Zoe McQuilten
SCIENTIFIC REPORTS | NATURE PUBLISHING GROUP | Published : 2017
To identify risk factors for infection in patients with diffuse large B cell lymphoma (DLBCL) undergoing rituximab, cyclophosphamide, vincristine, adriamycin and prednisolone (R-CHOP) treatment. All patients with DLBCL who received R-CHOP from 2004-2014 in a tertiary Australian hospital were identified and information collected from hospital admission data, laboratory results and medical record review. Infection was defined as hospitalisation with an ICD-10-AM diagnostic code for infection. Risk factors for infection and association between infection and survival were modelled using Cox proportional hazards regression. Over the 10-year period there were 325 patients; 191 (58.8%) males, media..View full abstract
CDs' work has been funded by Amgen. Amgen provided financial assistance for the study but had no part in the design, conduct, analysis or preparation of the manuscript. S.O. has received speakers fees and clinical research funding from Roche. M.G., T.S., Z.M., R.S. and T.K. declare no potential conflict of interest.